1Crawford RJ, Gillon J, Yap PL, et al. Prevalence and epidemiologieal characteristics of hepatitis C in Scot- tish blood donors[J]. Trans{usion Med 1994, 4 (2) 121-124.
2Kleinman S, Busch MP, Hall L, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study[J]. JAMA , 1998,280(12) : 1080-1085.
3Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus[J]. MM-WR,2003,52(3):5-6.
6Tynell E,Norda R,Ekermo B,et al. False-reactive mi- crobiologic screening test results in Swedish blood donors-how big is the problem? A survey among blood centers and deferred donors [J]. Transfusion, 2007,47 (1) :80-89.
7Whittaker S ,Carter N, Arnold E,et al. Understanding the meaning of permanent deferral for blood donors [J]. Transfusion, 2008,48 (l) : 64-72.
8FDA Recommendations for the Management of Donors and units that are Initially Reactive for Hepatitis B Surface antigen (HBsAg)[Z]. [EB/OL]. http:// www. fda. gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatorylnformation/OtherRec- ommendationsforManufacturers/MemorandumtoBlood Estahlishments/UCM063011. pdf.December 2,1987.
9FDA Guidance for Industry. Nucleic Acid Testing(NAT) for Human Immunodeficiency Virus Type 1 (HIV 1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry [Z] [EB/OL]. http://www, fda. gov/downloads/Bio- logicsBloodVaecines/GuidanceCompliance Regulatory- Information/Guidances/Blood/UCM210270. pdf. May 2010.
10FDA Guidance for Industry. Requalification Method for Reentry of Blood Donors Deferred Because of Re- active Test Results for Antibody to Hepatitis B Core Antigen (Anti-HBc) [Z] [EB/OL]. http://www. fda. gov/downloads/BiologicsBloodVaccines/Guid- anceComplianceRegulatoryInformation/Guidances / Blood/UCM210268. pdf. May 2010.
9Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR,2003,52(3) :5-6.
10Tserenpuntsag B, Nelson K, Lamjav O, et al. Prevalence of and risk factors for hepatitis B and C infection among Mongolian blood donors. Transfusion ,2010,50 ( 1 ) :92-99.
3FDA. Guidance for industry, nueleic acid testing (NAT) for hu- man immunedeficiency vires type 1 ( HIV-1 ) and hepatitis C vi- res(HCV) :testing,preduct disposition,and donor deferral and rc- en-try,2005 -2010.
4FDA Guidance for Industry, Use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood com- po-nents,including source plasma, to reduce the risk of transmis- sion of hepatitis B virtls,2010-2012.
